The TGF-ß-AGR2 Axis in Targeted CD34+ CAFs: A Translational Study Exploring Its Role and Clinical Significance in Pancreatic Cancer Progression

Mechanistic studies on the role of the CD34-TGFß-AGR2 axis in pancreatic cancer.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600123658

Enrollment

Unknown

Registered

2026-04-28

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer.

Interventions

Tumor group:NA

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Chinese people aged 25 to 65. 2. Patients diagnosed with malignant pancreatic tumors by clinical physicians, who need to be further confirmed and have their pathological types determined through endoscopic puncture biopsy.

Exclusion criteria

Exclusion criteria: 1. EUS-FNB is technically not feasible. 2. No solid lesions were detected during the endoscopic ultrasound examination. 3. Anticoagulant or antiplatelet therapy that cannot be discontinued. 4. Severe coagulation dysfunction. 5. Other contraindicated medical conditions. 6. Vulnerable groups such as pregnant women or patients with mental disorders.

Design outcomes

Primary

Measure	Time frame
CD34+ fibroblasts;	—

Countries

China

Contacts

Public ContactWeiqing Chen

The Cancer Hospital Affiliated to Chongqing University

chenwq620712@163.com+86 139 8369 5334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026